Merck/Moderna vaccine and Summit/Akeso bispecific therapy among key highlights at ESMO 2026
The European Society of Medical Oncology (ESMO) meeting in Madrid this weekend will showcase several high‑profile oncology programs.
Among the most watched are Merck and Moderna’s personalized cancer vaccine, which the partners highlighted earlier this year, and the PD‑1xVEGF bispecific antibody being developed by Summit Therapeutics together with Akeso Biopharma.
A range of antibody‑drug conjugates (ADCs) are also slated for presentation, reflecting the continued interest in this class of targeted therapies.
Analysts, such as Dara Azar of Stifel, note that the data could shape future investment opportunities in cancer immunotherapy.
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026”
read at BioSpace ↗
comments(0)
5-min edit window · permanent after that